International Laboratories, LLC Issues Voluntary Nationwide Recall of one (1) Lot of Clopidogrel Tablets USP, 75 mg packaged in bottles of 30 tablets Due to Mislabeling NDC # 54458-888-16; Lot # 117099A
International Laboratories, LLC is voluntarily recalling Lot# 117099A of Clopidogrel Tablets, USP 75 mg, packaged in bottles of 30 tablets, to the consumer level due to mislabeling. The product is labeled as Clopidogrel tablets USP 75 mg but may contain Clopidogrel 75mg or Simvastatin Tablets USP 10 mg. (Source: Food and Drug Administration)
Source: Food and Drug Administration - January 10, 2018 Category: Food Science Source Type: news
Clopidogrel After 1 Month in Stabilized ACS Patients Clopidogrel After 1 Month in Stabilized ACS Patients
A new study investigates switching from prasugrel or ticagrelor to clopidogrel vs. continuing either drug after a PCI for ACS. Will the results change clinical practice?European Heart Journal (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 28, 2017 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news
PRAGUE-18 Hints at Risk-Based Personalized DAPT After STEMI-PCI Discharge PRAGUE-18 Hints at Risk-Based Personalized DAPT After STEMI-PCI Discharge
Those who substituted clopidogrel for prasugrel or ticagrelor to avoid their steep out-of-pocket expense in the Czech trial, a lower-risk group as it turned out, didn ' t have more ischemic events.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 15, 2017 Category: Consumer Health News Tags: Cardiology News Source Type: news
Blood-thinning drugs may reduce dementia risk in people with irregular heartbeats
Conclusion
If you’ve been diagnosed with AF and you have been prescribed anticoagulant treatments such as warfarin or clopidogrel, we already know they protect you against having a stroke. This study suggests they may also help to protect you against dementia.
Cutting the risk of dementia for people who have a raised risk because of AF would be an exciting step forward. Unfortunately, we can’t tell from this study whether the protection against dementia was down to the anticoagulants, because of the possible effect of unmeasured confounding factors.
Usually, we would want to see a randomised controlled trial (RCT) to f...
Source: NHS News Feed - October 25, 2017 Category: Consumer Health News Tags: Neurology Source Type: news
You won ’t believe what happened this morning
When I got to the office this morning, several of my employees were in a state of near-panic…
I couldn’t imagine what might have happened… and I was alarmed.
Turns out, the coffee maker was on the fritz.
Coffee is the “drug” of choice for many of the people on my staff. And they’re not alone…
An astounding 80% of Americans use the caffeine in coffee to boost their energy. The buzz helps them wake up every morning and gets their day going.
And older adults drink coffee more than anyone else. In fact, in a survey by the National Coffee Association, 20% of people over 64 said they would rather gi...
Source: Al Sears, MD Natural Remedies - October 5, 2017 Category: Complementary Medicine Authors: Al Sears Tags: Anti-Aging Source Type: news
Judge: Firms must have permanent, physical presence in Delaware to file patent suits there
The District of Delaware Chief Judge said this week that businesses must have permanent residences in the state to be sued for patent infringement within it, following a series of US Supreme Court rulings, and transferred a patent spat case to Indiana.
Chief Judge Leonard Stark said the precedent was set after the Supreme Court’s decision in TC Heartland LLC v. Kraft Food Group Brands and Bristol-Myers Squibb Co. v. Superior Court of California earlier this year.
In TC Heartland v. Kraft Foods Group Brands, the Supremes limited the ability of patent holders to sue in other states. Kraft sued TC Heartland in its incorpo...
Source: Mass Device - September 13, 2017 Category: Medical Devices Authors: Fink Densford Tags: Legal News Boston Scientific Cook Medical Source Type: news
Platelet Testing Guides Prasugrel-to-Clopidogrel Switch Post-ACS Platelet Testing Guides Prasugrel-to-Clopidogrel Switch Post-ACS
The TROPICAL-ACS trial has validated a new"deescalation" regimen of antiplatelet therapy that could be applicable to patients unsuitable for long-term potent therapy due to bleeding or affordability concerns.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 8, 2017 Category: Consumer Health News Tags: Cardiology News Source Type: news
Ticagrelor for DAPT Again Questioned in Modern-Era PCI for ACS Ticagrelor for DAPT Again Questioned in Modern-Era PCI for ACS
More bleeds than clopidogrel without a clinical upside: Maybe ticagrelor isn ' t the best for dual antiplatelet therapy in PCI for ACS, given the prowess of modern drug-eluting stents, researchers say.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 30, 2017 Category: Consumer Health News Tags: Cardiology News Source Type: news
ESC: Ticagrelor Fails to Improve on Clopidogrel After Switch
(MedPage Today) -- Single-center study contradicts PLATO in ACS patients (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - August 29, 2017 Category: Cardiology Source Type: news
FDA Drug Safety Communication: Reduced effectiveness of Plavix (clopidogrel) in patients who are poor metabolizers of the drug
[03-12-2010] The U.S. Food and Drug Administration (FDA) has added a Boxed Warning to the label for Plavix, the anti-blood clotting medication. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - August 3, 2017 Category: Drugs & Pharmacology Source Type: news
Late Stent Events Linked to Response to Clopidogrel, Not ASA
(MedPage Today) -- Longer-term trial data suggests limited value to platelet reactivity testing (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - August 3, 2017 Category: Cardiology Source Type: news
Medical device makers look to slip lawsuits on Supreme Court ruling
A trio of medical device makers are looking to slip patent infringement and product liability lawsuits based on recent U.S. Supreme Court rulings governing out-of-state lawsuits.
In TC Heartland v. Kraft Foods Group Brands, the Supremes limited the ability of patent holders to sue in other states. Kraft sued TC Heartland in its incorporated state of Delaware over drink powder patents; a lower court blocked TC Heartland’s bid to move the case to its home base of Indiana. In May, the Supreme court reversed that decision, finding that the only place a defendant can be subject to a suit is their home court, a place where i...
Source: Mass Device - July 5, 2017 Category: Medical Devices Authors: Brad Perriello Tags: Legal News Patent Infringement Abbott Boston Scientific Ethicon johnsonandjohnson Personal Injury stjudemedical Source Type: news
Supremes tighten the rules on out-of-state lawsuits
The Supreme Court this week put limits on where injuries lawsuits can be fired, siding with businesses to prevent plaintiffs from “shopping” for friendly courts.
The justices overturned a lower court’s decision that had allowed out-of-state patients who took Bristol-Myers Squibb’s Plavix blood-thinning medication to file a suit against the company in California.
Under the justice’s ruling, state courts cannot hear claims against companies that are not based in the state where the injuries occurred. The Supreme Court arrived at a similar conclusion in a separate case in May 30.
Businesses can typically be sued in ...
Source: Mass Device - June 19, 2017 Category: Medical Devices Authors: Fink Densford Tags: Legal News Source Type: news
Prasugrel Fails to Show Noninferiority to Clopidogrel in Stroke Prasugrel Fails to Show Noninferiority to Clopidogrel in Stroke
Despite being a more potent antiplatelet agent, prasugrel failed to show noninferiority to clopidogrel in reducing vascular events in stroke patients in a new phase 3 trial.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 1, 2017 Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news
In ACS, Less Bleeding With Two-Step Post-PCI DAPT Strategy In ACS, Less Bleeding With Two-Step Post-PCI DAPT Strategy
Switching to clopidogrel after 1 month of prasugrel or ticagrelor reduces bleeding without increasing ischemic events in the open-label, single-center TOPIC study.Heartwire from Medscape (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 23, 2017 Category: Consumer Health News Tags: Cardiology News Source Type: news
